

**AMENDMENTS TO THE CLAIMS**

1-13. (canceled)

14. (previously presented ) A compound 20 to 80 nucleobases in length targeted to a nucleic acid molecule encoding forkhead box O1A, wherein the compound is at least 70% complementary to said nucleic acid molecule, wherein the compound inhibits the expression of said nucleic acid molecule, and wherein the compound comprises the nucleobase sequence of SEQ ID NO: 172.

15. (previously presented) An antisense oligonucleotide 8 to 80 nucleobases in length targeted to a the nucleic acid molecule of SEQ ID NO: 4 encoding forkhead box O1A, wherein the compound is at least 75% complementary to said nucleic acid molecule, wherein the compound inhibits the expression of said nucleic acid molecule, and wherein the compound comprises at least 8 consecutive nucleobases of SEQ ID NO: 172.

16-18. (canceled)

19. (Currently amended) A The compound of claim 14 which is an antisense oligonucleotide.

20. (Currently amended) A The compound of claim 19 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

21. (Currently amended) A The compound of claim 20 wherein the modified internucleoside linkage is a phosphorothioate linkage.

22. (Currently amended) A The compound of claim 19 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

23. (Currently amended) A The compound of claim 22 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

24. (Currently amended) A The compound of claim 19 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

25. (Currently amended) A The compound of claim 24 wherein the modified nucleobase is a 5-methylcytosine.

26. (Currently amended) A The compound of claim 19 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

27. (previously presented) A composition comprising the compound of claim 14 and a pharmaceutically acceptable carrier or diluent.

28. (Currently amended) ~~A~~ The composition of claim 27 further comprising a colloidal dispersion system.

29. (Currently amended) ~~A~~ The composition of claim 27 wherein the compound is an antisense oligonucleotide.

30. (Original) A method of decreasing the expression of forkhead box O1A in cells or tissues comprising contacting the cells or tissues with a compound of claim 1 so that expression of forkhead box O1A is decreased.

31. (Currently amended) ~~A~~ The method of claim 30 wherein the tissues or cells is liver or fat tissue or cells.

32. (Previously presented) A method of treating an animal having a disease or condition associated with forkhead box O1A comprising administering to the animal a therapeutically effective amount of a compound of claim 1 so that expression of forkhead box O1A is decreased.

33. (Currently amended) ~~A~~ The method of claim 32 wherein the disease or condition is a hyperproliferative disorder.

34. (Currently amended) ~~A~~ The method of claim 33 wherein the hyperproliferative disorder is cancer.

35. (Currently amended) ~~A~~ The method of claim 34 wherein the cancer is rhabdomyosarcoma.

36. (Currently amended) ~~A~~ The method of claim 32 wherein the disease or condition is diabetes.

37. (Currently amended) ~~A~~ The method of claim 36 wherein the diabetes is type 2.

38. (canceled)

39. (Previously presented) A method of decreasing blood or plasma glucose in an animal comprising administering to the animal a therapeutically effective amount of a compound of claim 1 so that expression of forkhead box O1A is decreased.

40. (Previously presented) A method of improving glucose tolerance in an animal comprising administering to the animal a therapeutically effective amount of a compound of claim 1 so that expression of forkhead box O1A is decreased.

41. (Previously presented) A method of normalizing insulin levels in an animal comprising administering to said animal a therapeutically effective amount of a compound of claim 1 so that expression of forkhead O1A is decreased.

42. (previously presented) An antisense oligonucleotide 15 to 30 nucleobases in length comprising at least 8 consecutive nucleobases of SEQ ID NO: 172 wherein the oligonucleotide is at least 75% complementary to the nucleic acid molecule of SEQ ID NO 4 encoding forkhead box O1A.

43. (canceled)

44. (Currently amended) ~~An~~ The antisense oligonucleotide of claim 42 wherein the oligonucleotide is at least 80% complementary to the nucleic acid molecule of SEQ ID NO 4 encoding forkhead box O1A.

45. (Currently amended) ~~An~~ The antisense oligonucleotide of claim 42 wherein the oligonucleotide is at least 90% complementary to the nucleic acid molecule of SEQ ID NO 4 encoding forkhead box O1A.

46. (Currently amended) ~~An~~ The antisense oligonucleotide of claim 42 wherein the oligonucleotide is at least 95% complementary to the nucleic acid molecule of SEQ ID NO 4 encoding forkhead box O1A.

47. (Currently amended) ~~An~~ The antisense oligonucleotide of claim 42 wherein said oligonucleotide is 20 nucleobases in length.

48. (previously presented) A compound 20 nucleobases in length comprising the nucleobase sequence of SEQ ID NO: 172.

49. (previously presented) The compound of claim 48 further comprising at least one modified internucleoside linkage or at least one modified sugar moiety.

50. (previously presented) The compound of claim 48 further comprising at least one 2'-O-methoxyethyl sugar moiety.

51. (previously presented) The compound of claim 48 characterized by a ten deoxynucleotide gap flanked on its 5' and 3' ends with 5' 2'-O-methoxyethyl nucleotides.

52. (previously presented) The compound of claim 51 further comprising phosphorothioate linkages for each internucleoside linkage.

53. (previously presented) The compound of claim 51 further comprising a 5-methylcytosine for each cytosine.